T2 Biosystems is developing innovative diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics.
 
The tests developed on the T2Dx Instrument have the following characteristics:
Rapid: Species-specific results in 3 to 5 hours with no up-front sample preparation.
Simple: Fully automated system.
Sensitive: Limit of detection of as low as 1 CFU/mL.
Blood matrix compatible: No blood culture required.
 
Currently available products:
T2Dx Instrument for use with T2Candida and T2Bacteria panels.
T2Candida Panel for the detection of C. albicans, C. tropicalis, C. parapsilosis, C. krusei and C. glabrata from whole blood samples.
T2Bacteria Panel for the detection of clinical relevant bacteria (4 gram negative, 2 gram positive) from whole blood samples.

Link to T2_Biosystems